Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more
Genovate Biotechnology Co Ltd (4130) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.012x
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has a cash flow conversion efficiency ratio of 0.012x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$16.93 Million) by net assets (NT$1.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genovate Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genovate Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arbor Technology
TWO:3594
|
-0.017x |
|
Kintor Pharmaceutical Limited
PINK:KNTPF
|
-0.161x |
|
Crimson Wine
OTCQB:CWGL
|
0.013x |
|
President Bakery Public Company Limited
BK:PB
|
0.029x |
|
Aminex PLC
PINK:AEXFF
|
-0.033x |
|
IOL Chemicals and Pharmaceuticals Limited
NSE:IOLCP
|
0.006x |
|
Ballard Mining Ltd
AU:BM1
|
-0.005x |
|
Gajah Tunggal Tbk
JK:GJTL
|
0.068x |
Annual Cash Flow Conversion Efficiency for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Genovate Biotechnology Co Ltd from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.38 Billion | NT$43.79 Million | 0.032x | -16.58% |
| 2024-12-31 | NT$1.45 Billion | NT$55.11 Million | 0.038x | -34.11% |
| 2023-12-31 | NT$1.47 Billion | NT$84.78 Million | 0.058x | +5293.20% |
| 2022-12-31 | NT$1.41 Billion | NT$1.51 Million | 0.001x | +108.55% |
| 2021-12-31 | NT$1.38 Billion | NT$-17.26 Million | -0.013x | -120.50% |
| 2020-12-31 | NT$1.43 Billion | NT$87.08 Million | 0.061x | +93.55% |
| 2019-12-31 | NT$1.41 Billion | NT$44.43 Million | 0.032x | -21.55% |
| 2018-12-31 | NT$1.56 Billion | NT$62.88 Million | 0.040x | +105.73% |
| 2017-12-31 | NT$1.60 Billion | NT$31.27 Million | 0.020x | -37.70% |
| 2016-12-31 | NT$2.25 Billion | NT$70.58 Million | 0.031x | +104.92% |
| 2015-12-31 | NT$2.12 Billion | NT$32.53 Million | 0.015x | -- |